425: Enzon Pharmaceuticals Implements Reverse Stock Split

Enzon Pharmaceuticals, Inc. announced a 1-for-100 reverse stock split and extended its Section 382 Rights Agreement, both in preparation for its merger with Viskase Companies, Inc.

Summary

• Enzon Pharmaceuticals, Inc. (the Company) entered into the Eleventh Amendment to the Section 382 Rights Agreement on March 23, 2026, extending the Final Expiration Date of the rights to noon, New York City time, on March 26, 2026.
• The Section 382 Rights Agreement, originally dated August 14, 2020, has been amended eleven times, with previous extensions on June 2, 2021, May 16, 2024, March 31, 2025, August 13, 2025, September 30, 2025, December 23, 2025, January 30, 2026, February 27, 2026, March 10, 2026, and March 18, 2026.
• A 1-for-100 reverse stock split (the Reverse Stock Split) became effective on March 24, 2026, at 4:30 p.m., Eastern Time.
• The Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026, under the temporary symbol ENZND for 20 trading days.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive a proportional cash payment based on the closing price on the last trading day preceding the effective time.
• The Reverse Stock Split is required prior to the completion of the contemplated merger between Enzon's wholly owned subsidiary and Viskase Companies, Inc.
• The reverse stock split also makes available authorized shares of common stock needed for the Company's outstanding exchange offer for its Series C Non-Convertible Redeemable Preferred Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting the procedural progression towards a significant strategic merger. While the reverse split addresses a technical requirement, the frequent extensions of the rights agreement suggest ongoing complexities, preventing a higher score.

Positives

• The completion of the reverse stock split is a necessary procedural step towards the anticipated merger with Viskase Companies, Inc., indicating progress on a strategic transaction.
• The extension of the Section 382 Rights Agreement is intended to protect the Company's valuable tax benefits, which management believes is in the best interests of the Company and its stockholders.

Negatives

• The frequent, short-term extensions of the Section 382 Rights Agreement (eleven amendments since August 2020) suggest ongoing uncertainty or a prolonged process in managing the Company's tax attributes or other strategic considerations.
• A 1-for-100 reverse stock split typically indicates a very low share price, which can be perceived negatively by investors, although in this case, it is a technical requirement for the merger and exchange offer.

Risks

• The risk that conditions to the closing of the proposed merger transaction are not satisfied, including failure to obtain necessary approvals.
• Uncertainties regarding the timing of the consummation of the proposed merger and exchange offer, including satisfaction of closing conditions.
• The ability of Viskase to timely deliver financial statements required by the Merger Agreement.
• The possibility that anticipated benefits of the proposed merger, such as revenues, expenses, earnings, growth, and tax treatment, may not be realized.
• Potential litigation relating to the proposed merger that could be instituted against Enzon, Viskase, or their respective officers or directors.
• Possible disruptions from the proposed merger that could harm Enzon's or Viskase's respective businesses.
• The ability of Viskase to retain, attract, and hire key personnel.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties resulting from the announcement or completion of the proposed merger.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed merger that could affect financial performance.
• Certain restrictions during the pendency of the proposed merger that may impact Enzon's or Viskase's ability to pursue certain business opportunities or strategic transactions.
• Uncertainty regarding the exchange ratio and relative ownership levels as of the closing of the merger.
• Estimates regarding future revenue, expenses, and capital requirements following the closing of the merger.
• Legislative, regulatory, and economic developments.
• Unpredictability and severity of catastrophic events, including acts of terrorism, trade wars, or outbreak of war or hostilities.

Future Outlook

The Company anticipates the closing of its merger with Viskase Companies, Inc. as soon as practicable after the expected expiration of the exchange offer on March 24, 2026. The common stock is expected to trade on a reverse stock split-adjusted basis on the OTCQB starting March 25, 2026, under the temporary symbol ENZND for 20 trading days.

Management Comments

• Management believes that extending the Final Expiration Date of the Section 382 Rights Agreement is in the best interests of the Company and its stockholders to preserve tax benefits.
• Richard L. Feinstein, CEO, CFO, and Secretary, signed the filing on behalf of Enzon Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that reverse stock splits are often utilized by companies with low share prices to meet listing requirements or, as in this case, to facilitate corporate transactions like mergers. While a reverse split can improve per-share metrics and market perception, its primary driver here is a strategic merger. The repeated extensions of the Section 382 Rights Agreement highlight the ongoing efforts to manage tax attributes, a common practice in M&A scenarios, but the frequency suggests a complex or prolonged process leading up to the Viskase merger.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase, or their respective officers or directors is identified as a risk.

Stakeholder Impact

• Shareholders: Will experience a 1-for-100 reverse stock split, resulting in fewer shares at a proportionally higher price. Those with fractional shares will receive cash. The actions are intended to facilitate a merger, which could ultimately impact long-term shareholder value.
• Employees: The merger introduces risks related to retention of key personnel, particularly at Viskase, as mentioned in the forward-looking statements.
• Customers and Suppliers: Potential adverse reactions or changes to relationships are identified as a risk during the pendency and completion of the merger.

Next Steps

• Common stock to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026.
• Common stock to trade under the temporary symbol ENZND for 20 trading days following the reverse split.
• Expiration of the exchange offer expected at 5:00 p.m., Eastern Time, on March 24, 2026.
• Closing of the merger with Viskase Companies, Inc. expected as soon as practicable after the exchange offer expiration.

Key Dates

Recommendation

The filing details procedural steps (reverse stock split, rights agreement extension) necessary for a previously announced merger and exchange offer. It does not provide new financial performance data or a change in strategic direction that would warrant a 'buy' or 'sell' recommendation. Investors are likely holding based on the prospects of the Viskase merger, and this filing confirms progress on the required corporate actions. The frequent extensions of the rights agreement and the nature of the reverse split suggest underlying complexities that temper a more aggressive stance.

Keywords

Reverse Stock Split, Merger, Viskase Companies, Section 382 Rights Agreement, Corporate Governance, SEC Filing, Pharmaceuticals, Exchange Offer, OTCQB